The 2020 Mid-Year Economic Update_long

Judge Certifies Class-Action Against McKesson in Pricing Battle

A U.S. District judge certified a class-action lawsuit Tuesday against pharmaceutical distributor McKesson Corp., San Francisco, CA, in a legal battle over drug pricing, according to law firm Hagen Berman.
&nbsp ;
The suit, originally filed in U.S. District Court in Boston, MA, in October 2006 on behalf of consumers and third-party payers, alleges that McKesson -one of the largest pharmaceutical distributors in North America -entered into a secret agreement to artificially inflate the reported average wholesale price of thousands of drugs, a benchmark used by Medicaid and insurance plans to determine payment to pharmacies.
&nbsp ;
In her ruling, Judge Patti Saris certified the case as a class action representing millions of healthcare consumers who made co-payments on what ...

A U.S. District judge certified a class-action lawsuit Tuesday against pharmaceutical distributor McKesson Corp., San Francisco, CA, in a legal battle over drug pricing, according to law firm Hagen Berman.
&nbsp ;
The suit, originally filed in U.S. District Court in Boston, MA, in October 2006 on behalf of consumers and third-party payers, alleges that McKesson -one of the largest pharmaceutical distributors in North America -entered into a secret agreement to artificially inflate the reported average wholesale price of thousands of drugs, a benchmark used by Medicaid and insurance plans to determine payment to pharmacies.
&nbsp ;
In her ruling, Judge Patti Saris certified the case as a class action representing millions of healthcare consumers who made co-payments on what the suit alleges were artificially inflated drug prices.
&nbsp ;
According to the complaint, beginning in late 2001, McKesson and First Databank, a publishing company, reached an agreement on how the AWP would be set for brand-named drugs, and in doing so, raised the spread between the published AWP and the actual acquisition costs in an effort to increase profits.
&nbsp ;
Earlier this year First Databank reached a settlement with the plaintiffs which includes a rollback of AWP prices and an agreement to stop publishing the data.
&nbsp ;
According to the complaint, McKesson communicated the price increase to First Databank, who published the information.
&nbsp ;
In her ruling certifying the class, the judge cites that before 2000, McKesson estimated that 20% of drug manufacturers used a 25% markup, but by 2002, that number had increased to 95%.
&nbsp ;
The case claimed that McKesson violated federal Racketeer Influenced and Corrupt Organizations (RICO) act, and California consumer laws.

About the Author
Leave a Reply

Leave a Comment

Sign Up for the MDM Update Newsletter

The MDM update newsletter is your best source for news and trends in the wholesale distribution industry.

By subscribing, you are agreeing to MDM’s Privacy Policy.
Social Media Auto Publish Powered By : XYZScripts.com